T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

Rhea-AI Summary

T2 Biosystems (TTOO) has announced its financial results for the fourth quarter and full year of 2020 will be released on March 4, 2021. Management will also host a conference call at 4:30 p.m. ET to discuss these results. The company focuses on rapid detection of sepsis-causing pathogens, aiming to enhance patient care and reduce treatment costs. Its product lineup includes the T2Dx Instrument and various diagnostic panels powered by proprietary T2 Magnetic Resonance technology. Investors can access the call via live or archived webcasts on the company’s website.

Positive

• T2 Biosystems is a leader in rapid detection, enhancing patient care.
• The company has a comprehensive product line aimed at diagnosing sepsis and other pathogens.
• A strong pipeline of future products suggests potential growth.

Negative

• None.

LEXINGTON, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2020 after market close on Thursday, March 4, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-407-9208 (U.S.) or 201-493-6784 (International) five to ten minutes prior to the start time.

About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx^® Instrument, T2Candida^® Panel, the T2Bacteria^® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR^®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

FAQ

When will T2 Biosystems (TTOO) report its 2020 financial results?

T2 Biosystems will report its 2020 financial results on March 4, 2021.

What time is the T2 Biosystems conference call?

The conference call will take place at 4:30 p.m. Eastern Time on March 4, 2021.

How can investors access the T2 Biosystems conference call?

Investors can access the conference call through a live and archived webcast on the T2 Biosystems website.

What is T2 Biosystems' focus in the healthcare market?

T2 Biosystems focuses on the rapid detection of sepsis-causing pathogens to improve patient care and reduce healthcare costs.